Traws Pharma, Inc. (TRAW)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Traws Pharma, Inc. reported revenue of $2.79M, up 1134.5% from the prior year. The company was profitable, with a net margin of 328.7%. It held $10.62M in total assets against $11.25M in total liabilities.
Key ratios (FY2025)
-640.7%
Operating margin
328.7%
Net margin
+1134.5%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.79M | $226.0K | $226.0K | $226.0K | $226.0K | $231.0K | $2.18M | $1.23M | $787.0K | $5.55M |
| Operating Income | -$17.88M | -$142.37M | -$20.30M | -$19.63M | -$16.50M | -$24.99M | -$21.70M | -$23.28M | -$25.74M | -$23.70M |
| Net Income | $9.17M | -$166.52M | -$18.95M | -$18.96M | -$16.16M | -$25.16M | -$21.50M | -$20.57M | -$24.09M | -$19.67M |
| EPS (Diluted) | $0.82 | $-35.21 | $-22.57 | $-0.91 | $-0.96 | $-2.17 | — | — | — | — |
| Total Assets | $10.62M | $24.96M | $22.68M | $39.37M | $55.48M | $19.99M | $23.67M | $17.92M | $4.98M | $23.23M |
| Total Liabilities | $11.25M | $56.59M | $12.01M | $11.06M | $9.36M | $13.81M | $12.10M | $12.54M | $15.84M | $18.11M |
| Shareholders' Equity | -$629.0K | -$31.63M | $10.67M | $28.31M | $46.12M | $6.17M | $11.57M | $5.39M | -$10.86M | $5.13M |
| Cash & Equivalents | — | — | $20.56M | $38.52M | — | — | — | — | — | $21.40M |
| Operating Cash Flow | -$18.18M | -$29.79M | -$17.93M | -$16.29M | -$19.49M | -$23.07M | -$20.83M | -$22.70M | -$23.82M | -$15.81M |
| Capital Expenditures | $2.58M | $3.65M | — | — | — | — | — | — | — | — |
| Shares Outstanding | 9.07M | 3.65M | 840.3K | 20.93M | 20.90M | 12.40M | 111.17M | 5.67M | 718.1K | 6.76M |